|
1
|
Montalto G, Cervello M, Giannitrapani L,
Dantona F, Terranova A and Castagnetta LA: Epidemiology, risk
factors, and natural history of hepatocellular carcinoma. Ann NY
Acad Sci. 963:13–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamanaka N, Okamoto E, Fujihara S, et al:
Do the tumor cells for hepatocellular carcinomas dislodge into the
portal venous stream during hepatic resection? Cancer.
70:2263–2267. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakashima T and Kojiro M: Hepatocellular
CarcinomaAn Atlas of Its Pathology. 7th. Springer Verlag; Tokyo:
1987
|
|
4
|
Wu MC, Chen H and Shen F: Surgical
treatment of primary liver cancer: a report of 5524 patients. Chin
J Surg. 39:25–28. 2001.
|
|
5
|
Zhang J, Gong F, Li L, et al: Diabetes
mellitus and the neutrophil to lymphocyte ratio predict overall
survival in non-viral hepatocellular carcinoma treated with
transarterial chemoembolization. Oncol Lett. 7:1704–1710.
2014.PubMed/NCBI
|
|
6
|
Llovet JM, Bustamante J, Castells A, et
al: Natural history of untreated nonsurgical hepatocellular
carcinoma: rationale for the design and evaluation of therapeutic
trials. Hepatology. 29:62–67. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lau WY, Lai EC and Yu SCH: Management Of
Portal Vein Tumor ThrombusHepatocellular Carcinoma. Lau WY: World
Scientific Publishing; Singapore: pp. 739–760. 2008, View Article : Google Scholar
|
|
8
|
Pugh RNH, Murray-Lyon IM, Dawson JL, et
al: Transection of the oesophagus for bleeding oesophageal varices.
Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kamath PS, Wiesner RH, Malinchoc M, et al:
A model to predict survival in patients with end-stage liver
disease. Hepatology. 33:464–470. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shuqun C, Mengchao W, Han C, et al: Tumor
thrombus types influence the prognosis of hepatocellular carcinoma
with the tumor thrombi in the portal vein. Hepatogastroenterology.
54:499–502. 2007.PubMed/NCBI
|
|
11
|
Shi J, Lai EC, Li N, et al: A new for
classification hepatocellular carcinoma with portal vein tumor
thrombus. J Hepatobiliary Pancreat Sci. 18:74–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen XP, Qiu FZ, Wu ZD, et al: Effects of
location and extension of portal vein tumor thrombus on long-term
outcomes of surgical treatment for hepatocellular carcinoma. Ann
Surg Oncol. 13:940–946. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arii S, Yamaoka Y, Futagawa S, et al:
Results of surgical and nonsurgical treatment for small-sized
hepatocellular carcinomas: A retrospective and nationwide survey in
Japan. The Liver Cancer Study Group of Japan. Hepatology.
32:1224–1229. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mazzaferro V, Regalia E, Doci R, et al:
Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DY, Park W, Lim DH, et al:
Three-dimensional conformal radiotherapy for portal vein thrombosis
of hepatocellular carcinoma. Cancer. 103:2419–2426. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bruix J, Sala M and Llovet JM:
Chemoembolization for hepatocellular carcinoma. Gastroenterology.
127 (5 Suppl 1):S179–S188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lo CM, Ngan H, Tso WK, et al: Randomized
controlled trial of transarterial lipiodol chemoembolization for
unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Federico A, Orditura M, Cotticelli G, et
al: Safety and efficacy of sorafenib in patients with advanced
hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol
Lett. 9:1628–1632. 2015.PubMed/NCBI
|
